S18986: A positive modulator of AMPA-receptors enhances (S)-AMPA-mediated BDNF mRNA and protein expression in rat primary cortical neuronal cultures

European Journal of Pharmacology

Volumn 561, Issue 1-3, 2007, Pages 23-31

  Lockhart, Brian Paul ^a   Rodriguez, Marianne ^a   Mourlevat, Sophie ^a   Peron, Philippe ^a   Catesson, Sandra ^a   Villain, Nadège ^a   Galizzi, Jean Pierre ^a   Boutin, Jean Albert ^a   Lestage, Pierre ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

AMPA receptor; BDNF; Hippocampus; Neurotrophin; Plasticity; S18986

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; 2,3 DIHYDRO 3,4 CYCLOPENTANO 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; 2,3 DIHYDRO [3,4]CYCLOPENTANO 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; AMPA RECEPTOR AGONIST; AMPA RECEPTOR ANTAGONIST; BENZOTHIADIAZINE DERIVATIVE; BRAIN DERIVED NEUROTROPHIC FACTOR; DIZOCILPINE; KAINIC ACID; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; HIPPOCAMPUS; NERVE CELL CULTURE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ALLOSTERIC REGULATION; ANIMALS; BENZOTHIADIAZINES; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELLS, CULTURED; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION; MENTAL DISORDERS; NEURONAL PLASTICITY; NEURONS; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; RATS; RECEPTORS, AMPA; RNA, MESSENGER;

EID: 33947289521     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.01.030     Document Type: Article

References (41)

1. Arai A., Guidotti A., Costa E., and Lynch G. Effect of the AMPA receptor modulator IDRA-21 on LTP responses in hippocampal slices. NeuroReport 7 (1996) 2211-2215
2. Arai A.C., Xia Y.F., Rogers G., Lynch G., and Kessler M. Benzamide-type AMPA receptor modulators form two subfamilies with distinct modes of action. J. Pharmacol. Exp. Ther. 303 (2002) 1075-1085
3. Ashby M.C., De La Rue S.A., Ralph G.S., Uney J., Collingridge G.L., and Henley J.M. Removal of AMPA receptors (AMPARs) from synapses is preceded by transient endocytosis of extrasynaptic AMPARs. J. Neurosci. 24 (2004) 5172-5176
4. Bartoletti A., Cancedda L., Reid S.W., Tessarollo L., Porciatti V., Pizzorusso T., and Maffei L. Heterozygous knock-out mice for brain-derived neurotrophic factor show a pathway-specific impairment of long-term potentiation by normal critical period for monocular deprivation. J. Neurosci. 22 (2002) 10072-10077
5. Black M.D. Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology 179 (2005) 154-163
6. Chao M.V. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat. Rev., Neurosci. 4 (2003) 299-309
7. Davies T.G., Pratt D.J., Endicott J.A., Johnson L.N., and Noble M.E. Structure-based design of cyclin-dependent kinase inhibitors. Pharmacol. Ther. 93 (2002) 125-133
8. Desos P., Lepagnol J.M., Morain P., Lestage P., and Cordi A.A. Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties. J. Med. Chem. 39 (1996) 197-206
9. Ernfors P., Kucera J., Lee K.F., Loring J., and Jaenisch R. Studies on the physiological role of brain-derived neurotrophic factor and neurotrophin-3 in knockout mice. Int. J. Dev. Biol. 39 (1995) 799-807
10. Gorski J.A., Balogh S.A., Wehner J.M., and Jones K.R. Learning deficits in forebrain-restricted brain-derived neurotrophic factor mutant mice. Neuroscience 121 (2003) 341-354
11. Granger R., Staubli U., Davis M., Perez Y., Nilsson L., Rogers G.A., and Lynch G. A drug that facilitates glutamatergic transmission reduces exploratory activity and improves performance in a learning-dependent task. Synapse 15 (1993) 326-329
12. Granger R., Deadwyler S., Davis M., Moskovitz B., Kessler M., Rogers G., and Lynch G. Facilitation of glutamate receptors reverses an age-associated memory impairment in rats. Synapse 22 (1996) 332-337
13. Hampson R.E., Rogers G., Lynch G., and Deadwyler S.A. Facilitative effects of the ampakine CX516 on short-term memory in rats: correlations with hippocampal neuronal activity. J. Neurosci. 18 (1998) 2748-2763
14. Hayashi T., Umemori H., Mishina M., and Yamamoto T. The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn. Nature 397 (1999) 72-76
15. Hoshaw B.A., Malberg J.E., and Lucki I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res. 1037 (2005) 204-208
16. Kernie S.G., Liebl D.J., and Parada L.F. BDNF regulates eating behavior and locomotor activity in mice. EMBO J. 19 (2000) 1290-1300
17. Kessler M., Mutneja M.S., Rogers G., and Lynch G. Regional preferences of AMPA receptor modulators determined through agonist binding autoradiography. Brain Res. 783 (1998) 121-126
18. Kovalchuk Y., Hanse E., Kafitz K.W., and Konnerth A. Postsynaptic induction of BDNF-mediated long-term potentiation. Science 295 (2002) 1729-1734
19. Lauterborn J.C., Lynch G., Vanderklish P., Arai A., and Gall C.M. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J. Neurosci. 20 (2000) 8-21
20. Lauterborn J.C., Truong G.S., Baudry M., Bi X., Lynch G., and Gall C.M. Chronic elevation of brain-derived neurotropic factor by ampakines. J. Pharmacol. Exp. Ther. 307 (2003) 297-305
21. Lebrun C., Pilliere E., and Lestage P. Effects of S 18986-1, a novel cognitive enhancer, on memory performances in an object recognition task in rats. Eur. J. Pharmacol. 401 (2000) 205-212
22. Legutko B., Li X., and Skolnick P. Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator. Neuropharmacology 40 (2001) 1019-1027
23. Lessmann V., Gottmann K., and Heumann R. BDNF and NT-4/5 enhance glutamatergic synaptic transmission in cultured hippocampal neurones. NeuroReport 6 (1994) 21-25
24. Levine E.S., Crozier R.A., Black I.B., and Plummer M.R. Brain-derived neurotropic factor modulates hippocampal synaptic transmission by increasing N-methyl-d-aspartic acid receptor activity. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 10235-10239
25. Lockhart B., Iop F., Closier M., and Lestage P. (S)-2,3-dihydro-[3,4]cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide: (S18986-1) a positive modulator of AMPA receptors enhances (S)-AMPA-mediated [3H]noradrenaline release from rat hippocampal and frontal cortex slices. Eur. J. Pharmacol. 401 (2000) 145-153
26. Mackowiak M., O'Neill M.J., Hicks C.A., Bleakman D., and Skolnick P. An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo study. Neuropharmacology 43 (2002) 1-10
27. Mamounas L.A., Blue M.E., Siuciak J.A., and Altar C.A. Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. J. Neurosci. 15 (1995) 7929-7939
28. Morales M., and Goda Y. Nomadic AMPA receptors and LTP. Neuron 21 (1999) 267-270
29. Narisawa-Saito M., Iwakura Y., Kawamura M., Araki K., Kozaki S., Takei N., and Nawa H. Brain-derived neurotropic factor regulates surface expression of alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid receptors by enhancing the N-ethylmaleimide-sensitive factor/GluR2 interaction in developing neocortical neurons. J. Biol. Chem. 277 (2002) 40901-40910
30. O'Neill M.J., Bleakman D., Zimmerman D.M., and Nisenbaum E.S. AMPA receptor potentiators for the treatment of CNS disorders. Curr. Drug Targets CNS Neurol. Disord. 3 (2004) 181-194
31. Parsons C.G., Danysz W., and Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect. 11 (1998) 523-569
32. Partin K.M., Patneau D.K., and Mayer M.L. Cyclothiazide differentially modulates desensitization of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor splice variants. Mol. Pharmacol. 46 (1994) 129-138
33. Patapoutian A., and Reichardt L.F. Trk receptors: mediators of neurotrophin action. Curr. Opin. Neurobiol. 11 (2001) 272-280
34. Rosi S., Giovannini M.G., Lestage P.J., Munoz C., Corte L.D., and Pepeu G. S18986, a positive modulator of AMPA receptors with cognition-enhancing properties, increases ACh release in the hippocampus of young and aged rat. Neurosci. Lett. 361 (2004) 120-123
35. Sekiguchi M., Takeo J., Harada T., Morimoto T., Kudo Y., Yamashita S., Kohsaka S., and Wada K. Pharmacological detection of AMPA receptor heterogeneity by use of two allosteric potentiators in rat hippocampal cultures. Br. J. Pharmacol. 123 (1998) 1294-1303
36. Thompson D.M., Guidotti A., DiBella M., and Costa E. 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide (IDRA-21), a congener of aniracetam, potently abates pharmacologically induced cognitive impairments in patas monkeys. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7667-7671
37. West A.E., Chen W.G., Dalva M.B., Dolmetsch R.E., Kornhauser J.M., Shaywitz A.J., Takasu M.A., Tao X., and Greenberg M.E. Calcium regulation of neuronal gene expression. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 11024-11031
38. Zafra F., Hengerer B., Leibrock J., Thoenen H., and Lindholm D. Activity dependent regulation of BDNF and NGF mRNAs in the rat hippocampus is mediated by non-NMDA glutamate receptors. EMBO J. 9 (1990) 3545-3550
39. Zafra F., Lindholm D., Castren E., Hartikka J., and Thoenen H. Regulation of brain-derived neurotrophic factor and nerve growth factor mRNA in primary cultures of hippocampal neurons and astrocytes. J. Neurosci. 12 (1992) 4793-4799
40. Zakharenko S.S., Patterson S.L., Dragatsis I., Zeitlin S.O., Siegelbaum S.A., Kandel E.R., and Morozov A. Presynaptic BDNF required for a presynaptic but not postsynaptic component of LTP at hippocampal CA1-CA3 synapses. Neuron 39 (2003) 975-990
41. Zivkovic I., Thompson D.M., Bertolino M., Uzunov D., DiBella M., Costa E., and Guidotti A. 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide (IDRA-21): a benzothiadiazine derivative that enhances cognition by attenuating dl-α-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA) receptor desensitization. J. Pharmacol. Exp. Ther. 272 (1995) 300-309